Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
60 participants
OBSERVATIONAL
2024-01-27
2034-01-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The Bone Morphogenetic Protein (BMP) pathway is involved in numerous functions, including self-renewal of the hematopoietic stem cell compartment and the regulation of hematopoiesis, via interaction with bone marrow stromal cells. Investigators have demonstrated its involvement in chronic myeloid leukemia (CML) and AML, in particular via the activation of TWIST1, ΔNp73, NANOG; it is responsible for an increased state of quiescence of certain cancer stem cells and their resistance.
Preliminary results based on the analysis of large databases suggest that the BMP pathway is also altered early in MDS. This study explores the alteration of this pathway in MDS and its involvement in the transformation into AML.
If appropriate, the BMP pathway could constitute a very promising therapeutic target to combat transformation into AML.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes
NCT03621241
Development of an in Vitro Hematopoietic Culture System and Application to Myelodysplastic Syndromes.
NCT03107273
Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70
NCT05367583
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy
NCT01235572
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
NCT06599762
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MDS patients
Adult patients with myelodysplastic syndrome or suspected myelodysplastic syndrome according to the criteria defined by the World Health Organization:
* one or more cytopenias,
* and/or dysplasia of one or more lines,
* and/or bone marrow blastosis
* and/or sideroblasts in medullary crowns
* and/or genetic/cytogenetic abnormalities characteristic of MDS.
* Whatever the R-IPSS stage (Revised International Prognostic Scoring System)
* No history of cytotoxic treatment (hydroxycarbamide, azacytidine)
Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care
When bone marrow is collected as part of a patient's care (diagnosis, follow-up, suspected AML/MDS hemopathy), one or two additional EDTA tubes of marrow are collected. Certain hematological data (NFP, genetic and molecular characteristics) will be collected in anonymized form and correlated with the BMP pathway alterations measured.
AML patients
Adult patients with suspected de novo acute myeloid leukemia at initial management
Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care
When bone marrow is collected as part of a patient's care (diagnosis, follow-up, suspected AML/MDS hemopathy), one or two additional EDTA tubes of marrow are collected. Certain hematological data (NFP, genetic and molecular characteristics) will be collected in anonymized form and correlated with the BMP pathway alterations measured.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care
When bone marrow is collected as part of a patient's care (diagnosis, follow-up, suspected AML/MDS hemopathy), one or two additional EDTA tubes of marrow are collected. Certain hematological data (NFP, genetic and molecular characteristics) will be collected in anonymized form and correlated with the BMP pathway alterations measured.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patient with suspicion of de novo acute myeloid leukemia at initial treatment
Exclusion Criteria
* MDS and AML having already benefited from cytotoxic treatment including hydroxycarbamide, azacytidine, intensive chemotherapy
* Patients objecting to their inclusion in the study
* Pregnant or breastfeeding women
* Patients under legal protection measure
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospices Civils de Lyon
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Maël MD HEIBLIG
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
69HCL22_0491
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.